Imatinib mesylate induced skin hypopigmentation [1]

Journal of Association of Physicians of India

Volumn 55, Issue JULY, 2007, Pages 527-

  Talwar, V ^a   Doval, D C ^a   Bhatia, Komal ^a  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPOPIGMENTATION; LETTER; ONCOGENE; SKIN DISEASE;

ANTINEOPLASTIC AGENTS; GENES, ABL; HUMANS; HYPOPIGMENTATION; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SKIN DISEASES;

EID: 34347386476     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8.
2. Nomura K, Hatayama I, Narita T, Kaneko T, Shiraishi M. A novel KIT gene missense mutation in a Japanese family with piebaldism. J Invest Dermatol 1998;111:337-8.
3. Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol 2002;20:869-70.